Charles A. Deignan

2022

In 2022, Charles A. Deignan earned a total compensation of $876K as Chief Financial Officer at Clearside Biomedical, a 43% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$138,250
Option Awards$237,791
Salary$388,650
Stock Awards$101,288
Other$10,050
Total$876,029

Deignan received $388.7K in salary, accounting for 44% of the total pay in 2022.

Deignan also received $138.3K in non-equity incentive plan, $237.8K in option awards, $101.3K in stock awards and $10.1K in other compensation.

Rankings

In 2022, Charles A. Deignan's compensation ranked 3,314th out of 5,753 executives tracked by ExecPay. In other words, Deignan earned more than 42.4% of executives.

ClassificationRankingPercentile
All
3,314
out of 5,753
42nd
Division
Manufacturing
1,868
out of 3,133
40th
Major group
Chemicals And Allied Products
889
out of 1,419
37th
Industry group
Drugs
832
out of 1,320
37th
Industry
Pharmaceutical Preparations
606
out of 966
37th
Source: SEC filing on April 28, 2023.

Deignan's colleagues

We found two more compensation records of executives who worked with Charles A. Deignan at Clearside Biomedical in 2022.

2022

George Lasezkay

Clearside Biomedical

Chief Executive Officer

2022

Thomas Ciulla

Clearside Biomedical

Chief Medical Officer

News

You may also like